CA2014889C - Intra-rectal pharmaceutical foam compositions - Google Patents
Intra-rectal pharmaceutical foam compositions Download PDFInfo
- Publication number
- CA2014889C CA2014889C CA002014889A CA2014889A CA2014889C CA 2014889 C CA2014889 C CA 2014889C CA 002014889 A CA002014889 A CA 002014889A CA 2014889 A CA2014889 A CA 2014889A CA 2014889 C CA2014889 C CA 2014889C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- foam
- amount
- water
- aminosalicylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Abstract
Pharmaceutical compositions suitable for intra-rectal administration in the form of a foam are described which comprise a therapeutically effective amount of 5-aminosalicylic acid; a pharmaceutically acceptable aqueous carrier therefor, and means for generating a foam.
Methods for their preparation and their use in the treatment of ulcerative colitis are also described.
Methods for their preparation and their use in the treatment of ulcerative colitis are also described.
Description
INTRA-RECTAL PHARMACEUTICAL FOAM COMPOSITIONS
The present invention relates to a pharmaceutical composition for rectal administration, to a method for its preparation, and to its use in the treatment of ulcerative colitis.
Ulcerative colitis is an inflammatory disease of the colon which is characterised by severe inflammation of the colonic and rectal mucosa and profuse diarrhoea and bleeding. The disease can occur at any age and affects both sexes equally. The prevalence of the disease is greatest in Western society and is estimated to be in the region of 50 to 70 sufferers per 100,000 members of the population - see, for example, the article by P. Baker, The Pharmaceutical Journal, August 6, 1988, page 180.
It is known that sulphasalazine and its metabolite, 5-aminosalicylic acid (5-ASA), are useful in the treatment of ulcerative colitis and a number of products containing these active ingredients are currently sold for this purpose.
A problem with 5-ASA is that it is absorbed in the small intestine and hence, when administered orally, does not reach the colon where it is required to exert a localised topical effect at the site of disease.
Several solutions to this problem have been proposed.
One known solution is to administer 5-ASA orally in a' polymeric coating which does not break down to release w the 5-ASA until the lower ileum/colon is reached. This approach has been described in, for example, US Patent 4,496,553. A drawback with this approach is that, in general, the 5-ASA is delivered to the proximal colon, but may not reach the distal colon in therapeutic concentrations.
~0~4889 Another solution is to administer the 5-ASP directly to the colon by means of rectal administration and it is known to administer 5-ASA in this way by means of suppositories and enemas.
Suppositories suffer from the disadvantage that they show relatively little spreading in the rectum/colon and thus the 5-ASA is not distributed widely throughout the diseased region. Enemas suffer from several disadvantages. Firstly, liquid formulations of 5-ASA
are relatively unstable and require special precautions to be taken in order that oxidative decomposition be avoided - see US 4,657,900. Secondly, there is the problem of leakage of the enema liquid from the rectum.
Leakage leads not only to a reduction in efficacy of the treatment, since contact time of the 5-ASA with the diseased area is reduced, but can also give rise to the unpleasant problem of stained clothing. The tendency of 5-ASA to acquire a brownish colour when oxidised means that this can be a particular problem.
It has now been found that the above-mentioned problems with existing rectal compositions of 5-ASA can be overcome by administering the 5-ASA in the form of an aqueous foam. The use of a foam overcomes the, problem of leakage while allowing the 5-ASA to spread efficiently through the diseased region of the colon.
In a first aspect, therefore, the present invention provides a pharmaceutical composition for intra-rectal administration in the form of a foam which comprises ' 5-aminosalicylic acid (5-ASA), a pharmaceutically acceptable aqueous carrier therefor and means for generating a foam.
The present invention relates to a pharmaceutical composition for rectal administration, to a method for its preparation, and to its use in the treatment of ulcerative colitis.
Ulcerative colitis is an inflammatory disease of the colon which is characterised by severe inflammation of the colonic and rectal mucosa and profuse diarrhoea and bleeding. The disease can occur at any age and affects both sexes equally. The prevalence of the disease is greatest in Western society and is estimated to be in the region of 50 to 70 sufferers per 100,000 members of the population - see, for example, the article by P. Baker, The Pharmaceutical Journal, August 6, 1988, page 180.
It is known that sulphasalazine and its metabolite, 5-aminosalicylic acid (5-ASA), are useful in the treatment of ulcerative colitis and a number of products containing these active ingredients are currently sold for this purpose.
A problem with 5-ASA is that it is absorbed in the small intestine and hence, when administered orally, does not reach the colon where it is required to exert a localised topical effect at the site of disease.
Several solutions to this problem have been proposed.
One known solution is to administer 5-ASA orally in a' polymeric coating which does not break down to release w the 5-ASA until the lower ileum/colon is reached. This approach has been described in, for example, US Patent 4,496,553. A drawback with this approach is that, in general, the 5-ASA is delivered to the proximal colon, but may not reach the distal colon in therapeutic concentrations.
~0~4889 Another solution is to administer the 5-ASP directly to the colon by means of rectal administration and it is known to administer 5-ASA in this way by means of suppositories and enemas.
Suppositories suffer from the disadvantage that they show relatively little spreading in the rectum/colon and thus the 5-ASA is not distributed widely throughout the diseased region. Enemas suffer from several disadvantages. Firstly, liquid formulations of 5-ASA
are relatively unstable and require special precautions to be taken in order that oxidative decomposition be avoided - see US 4,657,900. Secondly, there is the problem of leakage of the enema liquid from the rectum.
Leakage leads not only to a reduction in efficacy of the treatment, since contact time of the 5-ASA with the diseased area is reduced, but can also give rise to the unpleasant problem of stained clothing. The tendency of 5-ASA to acquire a brownish colour when oxidised means that this can be a particular problem.
It has now been found that the above-mentioned problems with existing rectal compositions of 5-ASA can be overcome by administering the 5-ASA in the form of an aqueous foam. The use of a foam overcomes the, problem of leakage while allowing the 5-ASA to spread efficiently through the diseased region of the colon.
In a first aspect, therefore, the present invention provides a pharmaceutical composition for intra-rectal administration in the form of a foam which comprises ' 5-aminosalicylic acid (5-ASA), a pharmaceutically acceptable aqueous carrier therefor and means for generating a foam.
The composition will usually contain at least 15%
(w/w) 5-ASA, relative to the total weight of the composition, for example 15% (w/w) to 35% (w/w), and more particularly will contain between 18% (w/w) and 30% (w/w) 5-ASA.
In general the particle size of the 5-ASA will be such that at least 95% of the particles have an equivalent sphere diameter of less than 60u. The equivalent sphere diameter is the diameter of a sphere having the same volume as the particle; see "Particle Size Measurement", Chapter 4, T. Allen, 2nd Edn., Chapman & Hall, London, 1975.
The means for generating a foam typically comprises a liquid or liquefied gas propellant. Such propellants are well known in the art. In view of the sensitivity of 5-ASA to oxidation, a compressed air propellant is not used. Suitable propellants are hydrocarbons such as propane or butane or halogenated hydrocarbons such as chlorofluorohydrocarbons or fluorohydrocarbons.
Examples of such propellants include the ArctonTM
propellants obtainable from Imperial Chemical Industries Limited, Runcorn, Cheshire, U.K., the FreonTM
propellants obtainable from Du Pont fU.K.), Stevenage, Hertfordshire, U.K., and the Foran propellants obtainable from Atochem, Paris, France.
Preferably the propellant is selected such that its vapour pressure is in the range from approximately 200 td 350 kNM 2.
A particular propellant is a combination of dichloro-difluoromethane (e. g. Arcton 12) and 1,2-dichlorotetra-fluoroethane (e. g. Arcton 114) in the weight ratio 4:6.
~~~.~~89 The propellant typically is present in the composition in an amount corresponding to between 5% and 15% (w/w), for example approximately 8-l0% (w/w).
The carrier typically constitutes from 50% (w/w) to 90% (w/~i) of the composition, for example between 55 % and 65% (w/w).
The carrier is an aqueous carrier and can contain, in addition to water, a pharmaceutically acceptable water-soluble organic carrier, for example a polyalcohol such as a propylene glycol, glycerol or a polyethylene-glycol and mixtures thereof. The carrier will be one which is compatible with the rectal and colonic mucosa.
In one general embodiment, the carrier contains water in an amount from approximately 20% (w/w) to approximately 100% (w/w) and a water-soluble organic polyalcohol as defined hereinabove, in an amount from approximately 0% (w/w) to approximately 80% (w/w).
In a particular embodiment, the carrier contains 50-60%
(w/w) water and 40-50% (w/w) polyalcohol.
In order to assist generation of the foam, and to improve the consistency and structure of the composition, it is usual to employ a surfactant. The surfactant chosen will be one which is compatible with the rectal and colonic mucosa and will be present in an amount which achieves the desired pharmaceutical effect but which does not give rise to problems of irritation.
Particularly suitable surfactants are non-ionic surfactants.
Particular surfactants for use in the present compositions are partial esters of sorbitan and sorbitol and their polyoxyethylene derivatives, for example Polysorbate 20 or 80 and Spanl'M-type surfactants, in particular a mixture of sorbitan mono-oleate and Polysorbate 20.
Suitably the surfactant is present in an amount of up to 15~ (w/w) of the composition, preferably less than 12~ (w/w).
In order to stiffen the foam, an emulsifying wax will generally be included in the composition. Typical emulsifying waxes for use in the present compositions are non-ionic emulsifying waxes such as those described in the U.S. National Formulary (USNF) and "Martindale". The emulsifying wax described in the USNF is a waxy solid, prepared from cetostearyl alcohol containing a polyoxy-ethylene derivative of a fatty acid ester of sorbitan.
TM
One commercially available emulsifying wax is 'Polawax' which is obtainable from Croda Chemicals Ltd., Goole, U.K.
The emulsifying wax will usually be present in an amount of up to 2~ (w/w) of the total weight of the composition, preferably less than 1~ (w/w), for example an amount in the range 0.3 to 0.7~ (w/w).
The foam compositions will generally have a pH in the range from approximately 4 to 7 and can be buffered or unbuffered. Preferably the compositions are buffered and a particular buffering agent is a mixture of disodium hydrogen orthophosphate and sodium dihydrogen orthophosphate.
The compositions can also contain other ingredients such as preservatives, chelating agents and antioxidants.
Typical preservatives are those such as sodium benzoate, 2~i~~~~
(w/w) 5-ASA, relative to the total weight of the composition, for example 15% (w/w) to 35% (w/w), and more particularly will contain between 18% (w/w) and 30% (w/w) 5-ASA.
In general the particle size of the 5-ASA will be such that at least 95% of the particles have an equivalent sphere diameter of less than 60u. The equivalent sphere diameter is the diameter of a sphere having the same volume as the particle; see "Particle Size Measurement", Chapter 4, T. Allen, 2nd Edn., Chapman & Hall, London, 1975.
The means for generating a foam typically comprises a liquid or liquefied gas propellant. Such propellants are well known in the art. In view of the sensitivity of 5-ASA to oxidation, a compressed air propellant is not used. Suitable propellants are hydrocarbons such as propane or butane or halogenated hydrocarbons such as chlorofluorohydrocarbons or fluorohydrocarbons.
Examples of such propellants include the ArctonTM
propellants obtainable from Imperial Chemical Industries Limited, Runcorn, Cheshire, U.K., the FreonTM
propellants obtainable from Du Pont fU.K.), Stevenage, Hertfordshire, U.K., and the Foran propellants obtainable from Atochem, Paris, France.
Preferably the propellant is selected such that its vapour pressure is in the range from approximately 200 td 350 kNM 2.
A particular propellant is a combination of dichloro-difluoromethane (e. g. Arcton 12) and 1,2-dichlorotetra-fluoroethane (e. g. Arcton 114) in the weight ratio 4:6.
~~~.~~89 The propellant typically is present in the composition in an amount corresponding to between 5% and 15% (w/w), for example approximately 8-l0% (w/w).
The carrier typically constitutes from 50% (w/w) to 90% (w/~i) of the composition, for example between 55 % and 65% (w/w).
The carrier is an aqueous carrier and can contain, in addition to water, a pharmaceutically acceptable water-soluble organic carrier, for example a polyalcohol such as a propylene glycol, glycerol or a polyethylene-glycol and mixtures thereof. The carrier will be one which is compatible with the rectal and colonic mucosa.
In one general embodiment, the carrier contains water in an amount from approximately 20% (w/w) to approximately 100% (w/w) and a water-soluble organic polyalcohol as defined hereinabove, in an amount from approximately 0% (w/w) to approximately 80% (w/w).
In a particular embodiment, the carrier contains 50-60%
(w/w) water and 40-50% (w/w) polyalcohol.
In order to assist generation of the foam, and to improve the consistency and structure of the composition, it is usual to employ a surfactant. The surfactant chosen will be one which is compatible with the rectal and colonic mucosa and will be present in an amount which achieves the desired pharmaceutical effect but which does not give rise to problems of irritation.
Particularly suitable surfactants are non-ionic surfactants.
Particular surfactants for use in the present compositions are partial esters of sorbitan and sorbitol and their polyoxyethylene derivatives, for example Polysorbate 20 or 80 and Spanl'M-type surfactants, in particular a mixture of sorbitan mono-oleate and Polysorbate 20.
Suitably the surfactant is present in an amount of up to 15~ (w/w) of the composition, preferably less than 12~ (w/w).
In order to stiffen the foam, an emulsifying wax will generally be included in the composition. Typical emulsifying waxes for use in the present compositions are non-ionic emulsifying waxes such as those described in the U.S. National Formulary (USNF) and "Martindale". The emulsifying wax described in the USNF is a waxy solid, prepared from cetostearyl alcohol containing a polyoxy-ethylene derivative of a fatty acid ester of sorbitan.
TM
One commercially available emulsifying wax is 'Polawax' which is obtainable from Croda Chemicals Ltd., Goole, U.K.
The emulsifying wax will usually be present in an amount of up to 2~ (w/w) of the total weight of the composition, preferably less than 1~ (w/w), for example an amount in the range 0.3 to 0.7~ (w/w).
The foam compositions will generally have a pH in the range from approximately 4 to 7 and can be buffered or unbuffered. Preferably the compositions are buffered and a particular buffering agent is a mixture of disodium hydrogen orthophosphate and sodium dihydrogen orthophosphate.
The compositions can also contain other ingredients such as preservatives, chelating agents and antioxidants.
Typical preservatives are those such as sodium benzoate, 2~i~~~~
sorbic acid and the parahydroxybenzoates, e.g.
methylparahydroxybenzoate (methyl paraben) and propylparahydroxybenzoate (propyl paraben). A preferred antioxidant is sodium metabisulphite and advantageously this can be used in conjunction with a chelating agent such as a salt of EDTA, e.g. disodium edetate.
Advantageously the composition contains colloidal silica, for example the AerosilTM product obtainable from Degussa Ltd. of London, U.K. Suitably the colloidal silica is gresent in an amount corresponding to less than 1% (w/w); for example it can be present in an amount corresponding to approximately 0.4% (w/w) of the composition.
The compositions of the present invention will usually be presented in a suitable dispensing container, for example an aluminium aerosol container, fitted with a suitable metering valve. Such containers are well known in the art. Where desired, the container can be fitted or supplied together with an applicator device for insertion into the rectum to ensure more efficient administration of the foam.
The compositions of the present invention suitably will be presented in a container fitted with a valve adapted to dispense volumes of from approximately 2 cm3 to approximately 5 cm3. Such valves can be obtained from, for example, Lablabo of 5, Rue Roger Salengro, 92120 Montrouge, France.
The present compositions can be prepared by mixing the ingredients in an appropriate manner and then filling into a suitable dispensing container, for example as described in the Examples.
2(~1~~~~
methylparahydroxybenzoate (methyl paraben) and propylparahydroxybenzoate (propyl paraben). A preferred antioxidant is sodium metabisulphite and advantageously this can be used in conjunction with a chelating agent such as a salt of EDTA, e.g. disodium edetate.
Advantageously the composition contains colloidal silica, for example the AerosilTM product obtainable from Degussa Ltd. of London, U.K. Suitably the colloidal silica is gresent in an amount corresponding to less than 1% (w/w); for example it can be present in an amount corresponding to approximately 0.4% (w/w) of the composition.
The compositions of the present invention will usually be presented in a suitable dispensing container, for example an aluminium aerosol container, fitted with a suitable metering valve. Such containers are well known in the art. Where desired, the container can be fitted or supplied together with an applicator device for insertion into the rectum to ensure more efficient administration of the foam.
The compositions of the present invention suitably will be presented in a container fitted with a valve adapted to dispense volumes of from approximately 2 cm3 to approximately 5 cm3. Such valves can be obtained from, for example, Lablabo of 5, Rue Roger Salengro, 92120 Montrouge, France.
The present compositions can be prepared by mixing the ingredients in an appropriate manner and then filling into a suitable dispensing container, for example as described in the Examples.
2(~1~~~~
The compositions of the present invention would typically be used to administer approximately 1-4g of 5-ASA per day, for example by administering one or two doses of lg 5-ASA once or twice daily. However, the amount administered will depend upon the severity of the condition and ultimately would be at the discretion of the dispensing physician. Where desired, the rectal foams could be used in conjunction with the delayed-release oral preparations of 5-ASA such as the "Asacol"~ product, i.e. the product described in European Patent No. 97651.
Where desired, other therapeutically useful ingredients may be added, for example, steroids such as hydrocortisone and prednisolone.
The invention will now be illustrated by means of Examples.
g _ FOAM CONCENTRATE (WITHOUT ADDITION OF PROPELLANT1 g(w/w) Weight (g) 5-Aminosalicylic Acid 15.0 150.0 Polysorbate 80 0.25 2.5 Emulsifying Wax ('Polawax NF') , 0.5 5.0 , i M
Colloidal Silicon Dioxide ('Aerosil 200') 0.5 5.0 Sodium Metabisulphite 0.3 3.0 Disodium Edetate, dehydrate 0.1 1.0 Methylparahydroxybenzoate 0.2 2.0 Propylparahydroxybenzoate . 0.04 0.4 Disodium Hydrogen Orthophosphate, 12H20 1.19 11.9 Sodium Dihydrogen Orthophosphate, 2H20 0.52 5.2 Glycerol 15.0 150.0 TM
Macrogol 300 (Polyethylene Glycol 300) 15.0 150.0 Water, Deionised 43.4 434.0 20~4~~0 25% 5-ASA FOAM
' %(w/w) Weight (g) 5-Aminosalicylic Acid 25.0 150.0 Sorbitan mono-oleate ('Span 80') 0.25 1.5 Emulsifying Wax ('Polawax NF') 0.5 3.0 Colloidal Silicon Dioxide ('Aerosil 200') 0.5 3.0 Sodium Metabisulphite 0.3 1.8 Disodium Edetate, dehydrate 0.1 0.6 Methylparahydroxybenzoate 0.2 1.2 Propylparahydroxybenzoate 0.04 0.24 Disodium Hydrogen Orthophosphate, 12H2O 1.19 714 Sodium Dihydrogen Orthophosphate, 2H20 0.52 3.12 15.0 90.0 Glycerol Macrogol 300 15.0 90.0 Propellants 'Arcton 12/114' 40:60 ~ 8.0 48.0 Water, Deionised 33.4 200.4 ~~1~~
25% 5-ASA FOAM CONCENTRATE
ywithout Addition of Propellant) %(w/w) Weight (g) 5-Aminosalicylic Acid 25.0 250.0 Emulsifying Wax ('Polawax NF') 0.75 7.5 Sodium Metabisulphite 0.3 3.0 Disodium Edetate, dihydrate 0.1 1.0 Methylparahydroxybenzoate 0.2 2.0 Propylparahydroxybenzoate o.04 o.4 Disodium Hydrogen Orthophosphate, 12H20 1.19 11.9 Sodium Dihydrogen Orthophosphate, 2H20 0.52 5.2 Water 63.9 639.0 2(~~.~~~~
25% 5-ASA FOAM CONCENTRATE
Swithout Addition of Propellant) %(w/w) Weight (g) 5-Aminosalicylic Acid 25.0 42.5 Propylene Glycol 30.0 51.0 Emulsifying Wax ('Polawax NF') 2.0 3.4 Sodium Metabisulphite 0.3 0.51 Disodium Edetate, dehydrate 0.1 0.17 Sodium Benzoate 0.1 0.17 Disodium Hydrogen orthophosphate, 12H20 1.0 1.7 Sodium Dihydrog~n Orthophosphate, 2H20 0.6 1.02 Water 35.95 61.115 20~.48~~
25% 5-ASA FOAM
%(w/w) Weight (g) 5-Aminosalicylic Acid 25.0 250.0 Polysorbate 80 0.25 2.50 Emulsifying Wax ('Polawax NF') 0.5 5.0 Colloidal Silicon Dioxide ('Aerosil 200') 0.5 5.0 Sodium Metabisulphite 0.3 3.0 Disodium Edetate, dehydrate 0.1 1.0 Methylparahydroxybenzoate 0.2 2.0 Propylparahydroxybenzoate 0.04 0.4 Disodium Hydrogen Orthophosphate, 12H20 1.19 11.9 Sodium Dihydrogen Orthophosphate, 2H20 0.52 5.2 Glycerol 15.0 150.0 Macrogol 300 15.0 150.0 Water, Deionised 33:4 334.0 Propellants 'Arcton 12/114' 40:60 8.0 80:0 22.5$ 5-ASA FOAM
%(w/w) Weight (g) 5-Aminosalicylic Acid 22.50 2.475 TM
Polysorbate 20 (Tween 20) 10.00 1.100 Emulsifying Wax ('Polawax NF') 0.40 0.044 Colloidal Silicon Dioxide (Aerosil 200) 0.40 0.044 Sodium Metabisulphite 0.30 0.033 Disodium Edetate, dehydrate 0.10 0.011 Methylparahydroxybenzoate 0.20 0.022 Propylparahydroxybenzoate 0.04 0.0044 Disodium Hydrogen Orthophosphate, 12H20 1.19 0.131 Sodium Dihydrogen Orthophosphate, 2H20 0.52 0.057 Glycerol 11.50 1.265 Macrogol 300 11.50 1.265 Water, Deionised 31.35 3.44 Propellants 'Arcton 12/114' 40:60 10.00 1.100 100.00 11.00 ~01~~~8 20% 5-ASA FOAM
~ %(w/w) Weight (g) 5-Aminosalicylic Acid 20.00 1.000 Sorbitan Mono-oleate 0.21 0.011 Polysorbate 20 7.80 0.390 Emulsifying Wax 0.43 0.022 Colloidal Silicon Dioxide 0.43 0.022 Sodium Metabisulphite 0.26 0.013 Disodium Edetate, dihydrate 0.10 0.005 Methylparahydroxybenzoate 0.20 0.010 Propylparahydroxybenzoate 0.04 0.002 Disodium Hydrogen Orthophosphate, 12H20 1.19 0.060 Sodium Dihydrogen Orthophosphate, 2H20 0.52 0.026 Glycerol 12.75 0.638 Macragol 300 12.75 0:638 Water, Deionised . 33.32 1.666 Propellants ~Arcton 12/114 40:60 10.00 0.500
Where desired, other therapeutically useful ingredients may be added, for example, steroids such as hydrocortisone and prednisolone.
The invention will now be illustrated by means of Examples.
g _ FOAM CONCENTRATE (WITHOUT ADDITION OF PROPELLANT1 g(w/w) Weight (g) 5-Aminosalicylic Acid 15.0 150.0 Polysorbate 80 0.25 2.5 Emulsifying Wax ('Polawax NF') , 0.5 5.0 , i M
Colloidal Silicon Dioxide ('Aerosil 200') 0.5 5.0 Sodium Metabisulphite 0.3 3.0 Disodium Edetate, dehydrate 0.1 1.0 Methylparahydroxybenzoate 0.2 2.0 Propylparahydroxybenzoate . 0.04 0.4 Disodium Hydrogen Orthophosphate, 12H20 1.19 11.9 Sodium Dihydrogen Orthophosphate, 2H20 0.52 5.2 Glycerol 15.0 150.0 TM
Macrogol 300 (Polyethylene Glycol 300) 15.0 150.0 Water, Deionised 43.4 434.0 20~4~~0 25% 5-ASA FOAM
' %(w/w) Weight (g) 5-Aminosalicylic Acid 25.0 150.0 Sorbitan mono-oleate ('Span 80') 0.25 1.5 Emulsifying Wax ('Polawax NF') 0.5 3.0 Colloidal Silicon Dioxide ('Aerosil 200') 0.5 3.0 Sodium Metabisulphite 0.3 1.8 Disodium Edetate, dehydrate 0.1 0.6 Methylparahydroxybenzoate 0.2 1.2 Propylparahydroxybenzoate 0.04 0.24 Disodium Hydrogen Orthophosphate, 12H2O 1.19 714 Sodium Dihydrogen Orthophosphate, 2H20 0.52 3.12 15.0 90.0 Glycerol Macrogol 300 15.0 90.0 Propellants 'Arcton 12/114' 40:60 ~ 8.0 48.0 Water, Deionised 33.4 200.4 ~~1~~
25% 5-ASA FOAM CONCENTRATE
ywithout Addition of Propellant) %(w/w) Weight (g) 5-Aminosalicylic Acid 25.0 250.0 Emulsifying Wax ('Polawax NF') 0.75 7.5 Sodium Metabisulphite 0.3 3.0 Disodium Edetate, dihydrate 0.1 1.0 Methylparahydroxybenzoate 0.2 2.0 Propylparahydroxybenzoate o.04 o.4 Disodium Hydrogen Orthophosphate, 12H20 1.19 11.9 Sodium Dihydrogen Orthophosphate, 2H20 0.52 5.2 Water 63.9 639.0 2(~~.~~~~
25% 5-ASA FOAM CONCENTRATE
Swithout Addition of Propellant) %(w/w) Weight (g) 5-Aminosalicylic Acid 25.0 42.5 Propylene Glycol 30.0 51.0 Emulsifying Wax ('Polawax NF') 2.0 3.4 Sodium Metabisulphite 0.3 0.51 Disodium Edetate, dehydrate 0.1 0.17 Sodium Benzoate 0.1 0.17 Disodium Hydrogen orthophosphate, 12H20 1.0 1.7 Sodium Dihydrog~n Orthophosphate, 2H20 0.6 1.02 Water 35.95 61.115 20~.48~~
25% 5-ASA FOAM
%(w/w) Weight (g) 5-Aminosalicylic Acid 25.0 250.0 Polysorbate 80 0.25 2.50 Emulsifying Wax ('Polawax NF') 0.5 5.0 Colloidal Silicon Dioxide ('Aerosil 200') 0.5 5.0 Sodium Metabisulphite 0.3 3.0 Disodium Edetate, dehydrate 0.1 1.0 Methylparahydroxybenzoate 0.2 2.0 Propylparahydroxybenzoate 0.04 0.4 Disodium Hydrogen Orthophosphate, 12H20 1.19 11.9 Sodium Dihydrogen Orthophosphate, 2H20 0.52 5.2 Glycerol 15.0 150.0 Macrogol 300 15.0 150.0 Water, Deionised 33:4 334.0 Propellants 'Arcton 12/114' 40:60 8.0 80:0 22.5$ 5-ASA FOAM
%(w/w) Weight (g) 5-Aminosalicylic Acid 22.50 2.475 TM
Polysorbate 20 (Tween 20) 10.00 1.100 Emulsifying Wax ('Polawax NF') 0.40 0.044 Colloidal Silicon Dioxide (Aerosil 200) 0.40 0.044 Sodium Metabisulphite 0.30 0.033 Disodium Edetate, dehydrate 0.10 0.011 Methylparahydroxybenzoate 0.20 0.022 Propylparahydroxybenzoate 0.04 0.0044 Disodium Hydrogen Orthophosphate, 12H20 1.19 0.131 Sodium Dihydrogen Orthophosphate, 2H20 0.52 0.057 Glycerol 11.50 1.265 Macrogol 300 11.50 1.265 Water, Deionised 31.35 3.44 Propellants 'Arcton 12/114' 40:60 10.00 1.100 100.00 11.00 ~01~~~8 20% 5-ASA FOAM
~ %(w/w) Weight (g) 5-Aminosalicylic Acid 20.00 1.000 Sorbitan Mono-oleate 0.21 0.011 Polysorbate 20 7.80 0.390 Emulsifying Wax 0.43 0.022 Colloidal Silicon Dioxide 0.43 0.022 Sodium Metabisulphite 0.26 0.013 Disodium Edetate, dihydrate 0.10 0.005 Methylparahydroxybenzoate 0.20 0.010 Propylparahydroxybenzoate 0.04 0.002 Disodium Hydrogen Orthophosphate, 12H20 1.19 0.060 Sodium Dihydrogen Orthophosphate, 2H20 0.52 0.026 Glycerol 12.75 0.638 Macragol 300 12.75 0:638 Water, Deionised . 33.32 1.666 Propellants ~Arcton 12/114 40:60 10.00 0.500
Claims (7)
1. A pharmaceutical composition suitable for intra-rectal administration in the form of a foam, which comprises a therapeutically effective amount of 5-aminosalicylic acid, a pharmaceutically acceptable aqueous carrier therefor which contains water in an amount from 20% (w/w) to 100% (w/w) and a water-soluble organic polyalcohol selected from a propylene glycol, glycerol or a polyethylene glycol and mixtures thereof, in an amount from 0% (w/w) to 80% (w/w) of the carrier, an emulsifying wax in an amount up to 2% (w/w) of the composition and means for generating a foam which is a liquid or liquefied gas propellant, wherein the 5-aminosalicylic acid is present in an amount corresponding to at least 15%
(w/w) of the composition.
(w/w) of the composition.
2. A composition according to claim 1 wherein the 5-aminosalicylic acid is present in an amount between 15% and 30% (w/w) of the composition.
3. A composition according to either claim 1 or claim 2 wherein the particle size of the 5-aminosalicylic acid is such that at least 95% of the particles have an equivalent sphere diameter of less than 60µ.
4. A composition according to any one of claims 1 to 3 wherein the carrier is a mixture of water and a water-soluble polyalcohol selected from propylene glycol, glycerol, or a polyethyleneglycol or a mixture thereof.
5. A composition according to any one of claims 1 to 4 which contains a non-ionic emulsifying wax in an amount corresponding to up to 2% (w/w) of the composition.
6. A composition according to any one of claims 1 to 5 which contains colloidal silica in an amount corresponding to up to 1% (w/w) of the composition.
7. A dispensing container suitable for dispensing a foam intrarectally, comprising an aerosol container fitted with a valve adapted to dispense volumes of from approximately 2ml to approximately 5ml and containing a composition as defined in any one of claims 1 to 6 and in which the means for generating a foam is a liquid or liquefied gas propellant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8909559.0 | 1989-04-26 | ||
| GB898909559A GB8909559D0 (en) | 1989-04-26 | 1989-04-26 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2014889A1 CA2014889A1 (en) | 1990-10-26 |
| CA2014889C true CA2014889C (en) | 2000-05-30 |
Family
ID=10655759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002014889A Expired - Lifetime CA2014889C (en) | 1989-04-26 | 1990-04-19 | Intra-rectal pharmaceutical foam compositions |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5082651A (en) |
| EP (1) | EP0395329B2 (en) |
| JP (1) | JP2566662B2 (en) |
| KR (1) | KR0179344B1 (en) |
| AT (1) | ATE124261T1 (en) |
| AU (1) | AU623245B2 (en) |
| CA (1) | CA2014889C (en) |
| DE (1) | DE69020422T3 (en) |
| DK (1) | DK0395329T4 (en) |
| ES (1) | ES2074124T5 (en) |
| GB (1) | GB8909559D0 (en) |
| GR (2) | GR3017367T3 (en) |
| HK (1) | HK1004521A1 (en) |
| IE (1) | IE67621B1 (en) |
| NZ (1) | NZ233415A (en) |
| PT (1) | PT93884B (en) |
| ZA (1) | ZA903127B (en) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9000485D0 (en) * | 1990-02-09 | 1990-02-09 | Pharmacia Ab | FOAMABLE COMPOSITION FOR PHARMACEUTICAL USE, USE THEREOF AND METHOD OF TREATMENT |
| IT1243379B (en) * | 1990-07-27 | 1994-06-10 | Giuliani Spa | PHARMACEUTICAL COMPOSITION SUITABLE FOR RECTAL ADMINISTRATION OF ACTIVE PRINCIPLES WHICH EXPLICATE A MEDICATION ACTION AT THE LEVEL OF THE COLON, PREVALENTLY TOPICAL |
| JP3425441B2 (en) * | 1990-10-22 | 2003-07-14 | ガストロ サービシイズ ピーティーワイ リミテッド | Treatment of non-inflammatory and non-infectious bowel disorders |
| IT1247529B (en) * | 1991-04-24 | 1994-12-17 | Poli Ind Chimica Spa | PHARMACEUTICAL COMPOSITIONS IN FOAM FORM FOR INTRAVAGINAL, SKIN AND ORAL ADMINISTRATION |
| AU1907992A (en) * | 1991-06-07 | 1993-01-08 | Byk Nederland Bv | Pharmaceutical enema preparation |
| FR2713486B1 (en) * | 1993-12-14 | 1996-02-09 | Scophysa | New compositions for foams, in particular rectal foams, and foams thus obtained. |
| DE4420735C2 (en) * | 1994-06-15 | 1996-09-05 | Allphamed Arzneimittel Gmbh | Process for the production of mechanically stable, high-speed effervescent tablets |
| GB9414699D0 (en) * | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
| GB9503119D0 (en) * | 1995-02-17 | 1995-04-05 | Durand Ltd | Medication and apparatus and method of applying medication |
| US6166024A (en) | 1995-03-30 | 2000-12-26 | Mayo Foundation For Medical Education And Research | Use of topical azathioprine and thioguanine to treat colorectal adenomas |
| US6326364B1 (en) | 1999-02-08 | 2001-12-04 | Cedars-Sinai Medical Center | Use of 5-aminosalicylates as antimicrobial agents |
| JP2001072576A (en) * | 1999-09-03 | 2001-03-21 | Kissei Pharmaceut Co Ltd | Oral medicinal composition |
| EP1214925B1 (en) * | 1999-09-06 | 2006-06-14 | Setsuko Ueda | Chemical peeling agent |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| TWI249519B (en) | 2000-08-29 | 2006-02-21 | Nobex Corp | Immunoregulatory compounds and derivatives and methods of treating diseases therewith |
| CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US8048924B2 (en) * | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| EP1312368A1 (en) * | 2001-11-19 | 2003-05-21 | Dr. Falk Pharma Gmbh | Composition comprising mesalazine for the treatment of inflammatory bowel diseases |
| WO2004037225A2 (en) * | 2002-10-25 | 2004-05-06 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
| IL152486A0 (en) * | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US20050186142A1 (en) * | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
| US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US10117812B2 (en) * | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US20070292355A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US20060193789A1 (en) * | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| US20080317679A1 (en) * | 2002-10-25 | 2008-12-25 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
| US20080206161A1 (en) * | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| US20050271596A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
| US20050069566A1 (en) * | 2003-08-04 | 2005-03-31 | Foamix Ltd. | Foam carrier containing amphiphilic copolymeric gelling agent |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US7704518B2 (en) * | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US20060233721A1 (en) * | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
| US20050205086A1 (en) * | 2002-10-25 | 2005-09-22 | Foamix Ltd. | Retinoid immunomodulating kit and composition and uses thereof |
| US9668972B2 (en) * | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US20070292359A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
| US8486376B2 (en) * | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| CN1856294A (en) * | 2003-08-25 | 2006-11-01 | 弗米克斯有限公司 | Penetrating pharmaceutical foam |
| US20100112088A1 (en) * | 2003-08-29 | 2010-05-06 | Jay Pravda | Materials and methods for treatment of disorders associated with oxidative stress |
| US8916546B2 (en) | 2003-08-29 | 2014-12-23 | Therapeutic Research Llc | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| ZA200507017B (en) * | 2004-02-04 | 2007-03-28 | Foamix Ltd | Cosmetic and pharmaceutical foam with solid matter |
| HUE028158T2 (en) | 2004-07-07 | 2016-12-28 | Biocon Ltd | Synthesis of azo bonded immunoregulatory compounds |
| US20080152596A1 (en) * | 2005-07-19 | 2008-06-26 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
| EP2061467A4 (en) * | 2006-09-08 | 2013-08-21 | Foamix Ltd | Colored or colorable foamable composition and foam |
| US20080260655A1 (en) * | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| EP2073794A2 (en) * | 2006-11-14 | 2009-07-01 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
| US7645801B2 (en) * | 2007-01-29 | 2010-01-12 | Alaven Pharmaceutical Llc | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
| MX2009013683A (en) * | 2007-06-13 | 2010-04-07 | Jay Pravda | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress. |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US20090130029A1 (en) * | 2007-11-21 | 2009-05-21 | Foamix Ltd. | Glycerol ethers vehicle and pharmaceutical compositions thereof |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| WO2009072007A2 (en) * | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| EP2242476A2 (en) * | 2008-01-14 | 2010-10-27 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| MX2012005883A (en) | 2009-11-23 | 2012-10-09 | Cipla Ltd | Topical foam composition. |
| CA2781579A1 (en) | 2009-11-23 | 2011-05-26 | Cipla Limited | Topical foam composition |
| US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
| AU2013342069B2 (en) | 2012-11-09 | 2018-05-31 | Haz Two, Llc | Enema composition for treatment of ulcerative colitis having long term stability |
| JP2015168654A (en) * | 2014-03-07 | 2015-09-28 | 三笠製薬株式会社 | Aqueous composition for nsaids containing foaming formulation |
| CA2978573A1 (en) | 2016-09-08 | 2018-03-08 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US20190351060A1 (en) * | 2016-12-16 | 2019-11-21 | Ferring B.V. | Rectal Foam Formulations |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1304682A (en) * | 1969-02-03 | 1973-01-24 | ||
| US3866800A (en) * | 1969-02-12 | 1975-02-18 | Alberto Culver Co | Non-pressurized package containing self-heating products |
| AU1314370A (en) * | 1970-02-09 | 1971-09-30 | Alberto-Culver Company | Gas-releasable and foamable compositions |
| US3997467A (en) * | 1971-11-26 | 1976-12-14 | Pharmacia Aktiebolag | Foam forming composition |
| US4112942A (en) * | 1974-10-09 | 1978-09-12 | Reckitt & Colman Products Limited | Method of preparing and administering a foam enema |
| AR205589A1 (en) * | 1974-10-09 | 1976-05-14 | Reckitt & Colmann Prod Ltd | INTRODUCING DEVICE OF AN AQUEOUS COMPOSITION INTO A BODY CAVITY |
| DE2755224A1 (en) * | 1976-12-15 | 1978-07-13 | Procter & Gamble | PAIN AND INFLAMMATION SOUNDING AGENT FOR LOCAL USE |
| US4211777A (en) * | 1977-11-25 | 1980-07-08 | Fisons Limited | Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid |
| WO1981002672A1 (en) * | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease |
| US4440763A (en) * | 1981-03-18 | 1984-04-03 | Block Drug Company, Inc. | Use of 4-aminosalicyclic acid as an anti-inflammatory agent |
| SU1172558A1 (en) * | 1983-07-11 | 1985-08-15 | Научно-исследовательский институт проктологии | Method of treatment of inflammatory diseases of large intestine |
| US4664256A (en) * | 1983-09-06 | 1987-05-12 | Farmaceutisk Laboratorium Ferring A/S | Packaged stable enema solution or suspension containing 5-aminosalicyclic acid |
| US4657900A (en) * | 1983-09-27 | 1987-04-14 | Rowell Laboratories | Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method |
| FR2561919B1 (en) * | 1984-04-03 | 1986-12-19 | Roussel Uclaf | PHARMACEUTICAL COMPOSITION CONSTITUTED ON THE ONE HAND, AS ACTIVE INGREDIENT, BY 9A, 11B-DICHLORO 16A-METHYL 21-OXYCARBONYLDICYCLOHEXYL METHYLOXY PREGNA-1,4-DIENE 3,20-DIONE AND ON THE OTHER HAND, BY A PHARM EXCIPIENT INERTE CAPABLE OF ALLOWING THE ACTION OF THE PRODUCT IN THE RECTUM OR THE COLON |
| US4639367A (en) * | 1985-03-18 | 1987-01-27 | Product Resources International, Inc. | Aerosol foam |
| US4752465A (en) * | 1985-09-20 | 1988-06-21 | Product Resources International, Inc. | Aerosol foam |
| US4889709A (en) * | 1985-03-18 | 1989-12-26 | Product Resources International, Inc. | Aerosol foam with adsorbate and container containing same |
| EP0251462A3 (en) * | 1986-05-28 | 1988-10-26 | Lloyd I. Osipow | Polymer-propellant compositions forming foamed structures |
| AU1388388A (en) * | 1987-04-01 | 1988-10-06 | Dak-Laboratoriet A/S | Benzoic acid derivatives and use thereof |
| US4945084A (en) * | 1987-07-08 | 1990-07-31 | Norman Oksman | Method and composition for topically treating anorectal or other dermal wounds |
-
1989
- 1989-04-26 GB GB898909559A patent/GB8909559D0/en active Pending
-
1990
- 1990-04-19 AU AU53672/90A patent/AU623245B2/en not_active Ceased
- 1990-04-19 KR KR1019900005452A patent/KR0179344B1/en not_active IP Right Cessation
- 1990-04-19 CA CA002014889A patent/CA2014889C/en not_active Expired - Lifetime
- 1990-04-23 ES ES90304314T patent/ES2074124T5/en not_active Expired - Lifetime
- 1990-04-23 DE DE69020422T patent/DE69020422T3/en not_active Expired - Lifetime
- 1990-04-23 NZ NZ233415A patent/NZ233415A/en unknown
- 1990-04-23 AT AT90304314T patent/ATE124261T1/en not_active IP Right Cessation
- 1990-04-23 EP EP90304314A patent/EP0395329B2/en not_active Expired - Lifetime
- 1990-04-23 DK DK90304314T patent/DK0395329T4/en active
- 1990-04-25 JP JP2111606A patent/JP2566662B2/en not_active Expired - Fee Related
- 1990-04-25 ZA ZA903127A patent/ZA903127B/en unknown
- 1990-04-25 US US07/514,634 patent/US5082651A/en not_active Expired - Lifetime
- 1990-04-25 IE IE146990A patent/IE67621B1/en not_active IP Right Cessation
- 1990-04-26 PT PT93884A patent/PT93884B/en not_active IP Right Cessation
-
1995
- 1995-09-13 GR GR950402484T patent/GR3017367T3/en unknown
-
1998
- 1998-04-28 HK HK98103610A patent/HK1004521A1/en not_active IP Right Cessation
-
2000
- 2000-02-03 GR GR20000400270T patent/GR3032575T3/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IE901469L (en) | 1990-10-26 |
| AU623245B2 (en) | 1992-05-07 |
| DE69020422T2 (en) | 1995-11-16 |
| KR900015741A (en) | 1990-11-10 |
| ATE124261T1 (en) | 1995-07-15 |
| KR0179344B1 (en) | 1999-03-20 |
| DK0395329T4 (en) | 2000-04-10 |
| GR3032575T3 (en) | 2000-05-31 |
| HK1004521A1 (en) | 1998-11-27 |
| DE69020422D1 (en) | 1995-08-03 |
| GR3017367T3 (en) | 1995-12-31 |
| GB8909559D0 (en) | 1989-06-14 |
| EP0395329A2 (en) | 1990-10-31 |
| IE67621B1 (en) | 1996-04-17 |
| AU5367290A (en) | 1990-11-01 |
| JP2566662B2 (en) | 1996-12-25 |
| NZ233415A (en) | 1991-05-28 |
| ES2074124T5 (en) | 2000-01-16 |
| DE69020422T3 (en) | 2000-03-30 |
| DK0395329T3 (en) | 1995-10-30 |
| EP0395329B2 (en) | 1999-11-17 |
| CA2014889A1 (en) | 1990-10-26 |
| ES2074124T3 (en) | 1995-09-01 |
| EP0395329A3 (en) | 1991-11-21 |
| PT93884B (en) | 1996-10-31 |
| JPH02295928A (en) | 1990-12-06 |
| US5082651A (en) | 1992-01-21 |
| PT93884A (en) | 1990-11-20 |
| EP0395329B1 (en) | 1995-06-28 |
| ZA903127B (en) | 1991-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2014889C (en) | Intra-rectal pharmaceutical foam compositions | |
| US8486375B2 (en) | Foamable compositions | |
| ES2209812T3 (en) | TOPIC SPRAYINGS CONTAINING A FILMOGENA COMPOSITION. | |
| CA2044676C (en) | Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level | |
| EP1519731B1 (en) | Combination of azelastine and fluticasone | |
| US20170157175A1 (en) | Foam containing benzoyl peroxide | |
| CA2637408C (en) | Foam-forming composition | |
| CA2302710A1 (en) | New foam-forming pharmaceutical composition | |
| HU226694B1 (en) | Medicinal aerosol products containing ciclesonide | |
| CA2861141A1 (en) | Oromucosal liquid estradiol compositions | |
| US4515810A (en) | Composition of matter | |
| US20220143046A1 (en) | Composition and methods for rectal delivery of 4-aapa and 5-asa compounds | |
| JP2003081812A (en) | Aerosol preparation | |
| EP1810666A1 (en) | Foam-Forming composition | |
| WO2018122086A1 (en) | Enema for rectal application | |
| ITMI962278A1 (en) | SPRAY PHARMACEUTICAL COMPOSITIONS FOR THE APPLICATION OF FORMULATES FOR TOPICAL USE CONTAINING ESCIN | |
| CZ283238B6 (en) | Liquid pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |